Spinocerebellar Ataxia (SCA) Pipeline Analysis report covers approximately 10 drugs currently in different phases of development. Spinocerebellar Ataxia (SCA) is a term referring to the group of genetic autosomal dominant diseases that causes degenerative changes in the cerebellum. Symptoms of the disease are an uncoordinated walk, decreased hand-to-eye coordination, dysarthria (slurred or abnormal speech), improper vision and involuntary eye movement and difficulty in processing, learning and remembering information. The disease is diagnosed through genetic testing and treatment options vary as per the type of SCA and signs and symptoms of SCA. The classification is done according to the mutated gene responsible for the type of ataxia and is describes as SCA followed by the number (SCA1 till SCA40).
The report provides Spinocerebellar Ataxia (SCA) treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.
Major industry players profiled as part of the report are Kissei Pharmaceutical Co., Ltd., Steminent Biotherapeutics Inc., and Wave Life Sciences among others.
Scope:
The report provides Spinocerebellar Ataxia (SCA) treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.
Major industry players profiled as part of the report are Kissei Pharmaceutical Co., Ltd., Steminent Biotherapeutics Inc., and Wave Life Sciences among others.
Scope:
- By Company
- By Phase
- By Molecule Type
- By Region
- By Route of Administration
Table of Contents
1. Introduction
2. Disease Overview
4. Market Dynamics
5. Pipeline Analysis/Outlook
6. Company profiling
Companies Mentioned
- Lacerta Therapeutics
- Kissei Pharmaceutical Co., Ltd.
- Biohaven Pharmaceutical
- Steminent Biotherapeutics Inc.
- Bioblast Pharma Ltd.
- Cadent Therapeutics
- Vybion
- Wave Life Sciences
- Shire
- Ionis
Methodology
LOADING...
